On September 29, 2019, shareholding voting in excess of 51% of the outstanding Common Stock of GNCC Capital, Inc.’s (“the Company”) Common Stock; passed a unanimous resolution and as follows:
That the Company’s acquisition of Bio Cann Pharma, S.A.S. be cancelled and declared null and void. That the Company is prohibited from issuing the shares of Common Stock and the shares of Series M Convertible Preferred Stock to the vendors of Bio Cann Pharma, S.A.S. This resolution was taken due to zero engagement from nor any accountability to the Company’s Directors.